Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct;5(10):1075-87.
doi: 10.2217/imt.13.102.

Targeting tumor-infiltrating macrophages to combat cancer

Roheena Z Panni  1 , David C Linehan, David G DeNardo
Affiliations
Review

Targeting tumor-infiltrating macrophages to combat cancer

Roheena Z Panni et al. Immunotherapy. 2013 Oct.

Abstract

Tumor-associated macrophages are one of the major constituents of tumor stroma in many solid tumors and there is compelling preclinical and clinical evidence that macrophages promote cancer initiation and malignant progression. Therefore, these cells represent potential targets for therapeutic benefit. In this review, we will summarize macrophage phenotypic heterogeneity, the current understanding of how tumors take advantage of macrophage plasticity to generate immunosuppression, and how manipulation of specific macrophage populations can be used for therapeutic purposes through translational approaches.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Properties of pro- and anti-tumor-associated macrophages
EMT: Epithelial-mesenchymal transition; IC: Immune complex; IM: Inflammatory monocyte; iNOS: Inducible nitric oxide synthase; ROI: Reactive oxygen intermediate; RM: Resident monocyte; TAM: Tumor-associated macrophage.
Figure 2
Figure 2. Strategies to target macrophages in blood and at different levels within the tumor
CD40L: CD40 ligand; CSF1R: CSF1 receptor; TAM: Tumor-associated macrophage; TLR: Toll-like receptor; VEGFR: VEGF receptor.
See this image and copyright information in PMC

References

    1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. - PubMed
    1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. - PMC - PubMed
    1. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol. 2007;19(2):203–208. - PubMed
    1. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005;5(12):953–964. - PubMed
    1. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–555. - PubMed

Websits

    1. A Study of IMC-CS4 in Subjects With Advanced Solid Tumors. www.clinicaltrials.gov/show/NCT01346358.
    1. A Study of AMG 820 in Subjects With Advanced Solid Tumors. www.clinicaltrials.gov/show/NCT01444404.
    1. Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors. www.clinicaltrials.gov/show/NCT01804530.
    1. Safety Study of PLX108-01 in Patients With Solid Tumors. www.clinicaltrials.gov/show/NCT01004861.
    1. S0916, MLN1202 in Treating Patients With Bone Metastases. www.clinicaltrials.gov/show/NCT01015560.

Publication types

Substances